---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104962"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:01:42.546819+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics Q2 net loss narrows to $134.4M; aficamten PDUFA set Dec 26, 2025

## Summary
- Net loss of $134.4M ($1.12/sh) vs $143.3M ($1.31/sh) in Q2 2024; revenue $66.8M from Bayer deal.
- Cash, cash equivalents and investments: $1.0B at June 30, down $52.6M QoQ after $75M loan draw.
- FDA late-cycle meeting for aficamten (obstructive HCM) scheduled Sept 2025; PDUFA Dec 26, 2025.
- MAPLE-HCM primary results to be presented in Hot Line Session at ESC 2025.
- FY 2025 GAAP operating expense guidance maintained at $670M-$710M.

## SEC filing metadata
- accession: 0000950170-25-104962
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/0000950170-25-104962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/cytk-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104962
- JSON: https://secwatch.observer/filing/0000950170-25-104962.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104962.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.